US6951271005 - Common Stock

**PCRX** gets a fundamental rating of **6** out of 10. The analysis compared the fundamentals against 198 industry peers in the **Pharmaceuticals** industry. **PCRX** has an excellent profitability rating, but there are some minor concerns on its financial health. **PCRX** is valued quite cheap, while showing a decent growth score. This is a good combination! With these ratings, **PCRX** could be worth investigating further for value investing!.

In the past year **PCRX** was profitable.

In the past year **PCRX** had a positive cash flow from operations.

Each year in the past 5 years **PCRX** had a positive operating cash flow.

With an excellent **Return On Equity** value of **4.83%**, **PCRX** belongs to the best of the industry, outperforming **87.18%** of the companies in the same industry.

Industry Rank | Sector Rank | ||
---|---|---|---|

ROA | 2.67% | ||

ROE | 4.83% | ||

ROIC | 4.02% |

ROA(3y)1.88%

ROA(5y)3.15%

ROE(3y)4.21%

ROE(5y)6.6%

ROIC(3y)4.32%

ROIC(5y)4.07%

With an excellent **Profit Margin** value of **6.23%**, **PCRX** belongs to the best of the industry, outperforming **86.15%** of the companies in the same industry.

In the last couple of years the **Profit Margin** of **PCRX** has declined.

In the last couple of years the **Operating Margin** of **PCRX** has grown nicely.

With a decent **Gross Margin** value of **72.65%**, **PCRX** is doing good in the industry, outperforming **78.97%** of the companies in the same industry.

Industry Rank | Sector Rank | ||
---|---|---|---|

OM | 12.94% | ||

PM (TTM) | 6.23% | ||

GM | 72.65% |

OM growth 3Y-2.79%

OM growth 5Y20.05%

PM growth 3Y-43.17%

PM growth 5YN/A

GM growth 3Y-0.03%

GM growth 5Y-0.43%

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so **PCRX** is destroying value.

Compared to 1 year ago, **PCRX** has more shares outstanding

The debt/assets ratio for **PCRX** has been reduced compared to a year ago.

With a decent **Altman-Z score** value of **1.89**, **PCRX** is doing good in the industry, outperforming **68.72%** of the companies in the same industry.

With an excellent **Debt to FCF ratio** value of **3.75**, **PCRX** belongs to the best of the industry, outperforming **89.23%** of the companies in the same industry.

A Debt/Equity ratio of **0.59** indicates that **PCRX** is somewhat dependend on debt financing.

Industry Rank | Sector Rank | ||
---|---|---|---|

Debt/Equity | 0.59 | ||

Debt/FCF | 3.75 | ||

Altman-Z | 1.89 |

ROIC/WACC0.55

WACC7.37%

A Current Ratio of **5.24** indicates that **PCRX** has no problem at all paying its short term obligations.

Looking at the **Current ratio**, with a value of **5.24**, **PCRX** is in the better half of the industry, outperforming **67.69%** of the companies in the same industry.

Looking at the **Quick ratio**, with a value of **4.17**, **PCRX** is in the better half of the industry, outperforming **61.03%** of the companies in the same industry.

Industry Rank | Sector Rank | ||
---|---|---|---|

Current Ratio | 5.24 | ||

Quick Ratio | 4.17 |

The **Earnings Per Share** has grown by an nice **12.74%** over the past year.

The **Earnings Per Share** has been growing by **22.93%** on average over the past years. This is a very strong growth

Looking at the last year, **PCRX** shows a small growth in **Revenue**. The Revenue has grown by **1.21%** in the last year.

EPS 1Y (TTM)12.74%

EPS 3Y9.9%

EPS 5Y22.93%

EPS growth Q2Q11.25%

Revenue 1Y (TTM)1.21%

Revenue growth 3Y16.25%

Revenue growth 5Y14.88%

Revenue growth Q2Q5.37%

The **Earnings Per Share** is expected to grow by **12.07%** on average over the next years. This is quite good.

The **Revenue** is expected to grow by **10.37%** on average over the next years. This is quite good.

EPS Next Y-2.82%

EPS Next 2Y11.46%

EPS Next 3Y14.4%

EPS Next 5Y12.07%

Revenue Next Year2.34%

Revenue Next 2Y6.04%

Revenue Next 3Y7.08%

Revenue Next 5Y10.37%

Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.

The **Price/Earnings** ratio is **8.87**, which indicates a very decent valuation of **PCRX**.

Based on the **Price/Earnings** ratio, **PCRX** is valued cheaply inside the industry as 92.82% of the companies are valued more expensively.

Compared to an average S&P500 **Price/Earnings** ratio of **25.25**, **PCRX** is valued rather cheaply.

The **Price/Forward Earnings** ratio is **9.13**, which indicates a very decent valuation of **PCRX**.

When comparing the **Price/Forward Earnings** ratio of **PCRX** to the average of the S&P500 Index (**21.67**), we can say **PCRX** is valued rather cheaply.

Industry Rank | Sector Rank | ||
---|---|---|---|

PE | 8.87 | ||

Fwd PE | 9.13 |

Compared to the rest of the industry, the **Enterprise Value to EBITDA** ratio of **PCRX** indicates a rather cheap valuation: **PCRX** is cheaper than 89.74% of the companies listed in the same industry.

Compared to the rest of the industry, the **Price/Free Cash Flow** ratio of **PCRX** indicates a rather cheap valuation: **PCRX** is cheaper than 91.79% of the companies listed in the same industry.

Industry Rank | Sector Rank | ||
---|---|---|---|

P/FCF | 8.63 | ||

EV/EBITDA | 8.38 |

PEG (NY)N/A

PEG (5Y)0.39

EPS Next 2Y11.46%

EPS Next 3Y14.4%

No dividends for **PCRX**!.

Industry Rank | Sector Rank | ||
---|---|---|---|

Dividend Yield | N/A |

**PACIRA BIOSCIENCES INC**

NASDAQ:PCRX (4/24/2024, 3:02:45 PM)

After market: 25.9 0 (0%)**25.9**

**-0.91 (-3.39%) **

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap1.20B

Analysts

Price Target

Dividend

Industry Rank | Sector Rank | ||
---|---|---|---|

Dividend Yield | N/A |

Dividend Growth(5Y)

DP

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

Industry Rank | Sector Rank | ||
---|---|---|---|

PE | 8.87 | ||

Fwd PE | 9.13 | ||

P/S | |||

P/FCF | |||

P/OCF | |||

P/B | |||

P/tB | |||

EV/EBITDA |

EPS(TTM)

EY

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)0.39

Profitability

Industry Rank | Sector Rank | ||
---|---|---|---|

ROA | 2.67% | ||

ROE | 4.83% | ||

ROCE | |||

ROIC | |||

ROICexc | |||

ROICexgc | |||

OM | 12.94% | ||

PM (TTM) | 6.23% | ||

GM | 72.65% | ||

FCFM |

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.43

Health

Industry Rank | Sector Rank | ||
---|---|---|---|

Debt/Equity | 0.59 | ||

Debt/FCF | |||

Debt/EBITDA | |||

Cap/Depr | |||

Cap/Sales | |||

Interest Coverage | |||

Cash Conversion | |||

Profit Quality | |||

Current Ratio | 5.24 | ||

Quick Ratio | 4.17 | ||

Altman-Z |

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)12.74%

EPS 3Y9.9%

EPS 5Y

EPS growth Q2Q

EPS Next Y-2.82%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)1.21%

Revenue growth 3Y16.25%

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y